OneAscent Financial Services LLC Acquires New Holdings in Johnson & Johnson (NYSE:JNJ)

OneAscent Financial Services LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 9,513 shares of the company's stock, valued at approximately $1,542,000. Johnson & Johnson accounts for approximately 1.1% of OneAscent Financial Services LLC's portfolio, making the stock its 14th biggest holding.

A number of other hedge funds have also bought and sold shares of the business. Summit Wealth Partners LLC grew its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company's stock worth $1,463,000 after buying an additional 61 shares during the last quarter. Powers Advisory Group LLC grew its stake in Johnson & Johnson by 0.6% during the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock worth $1,538,000 after buying an additional 61 shares during the last quarter. Citizens & Northern Corp grew its stake in Johnson & Johnson by 3.5% during the 2nd quarter. Citizens & Northern Corp now owns 1,884 shares of the company's stock worth $275,000 after buying an additional 63 shares during the last quarter. Eagle Wealth Strategies LLC grew its stake in Johnson & Johnson by 2.8% during the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company's stock worth $372,000 after buying an additional 63 shares during the last quarter. Finally, Epic Trust Investment Advisors LLC grew its stake in Johnson & Johnson by 3.6% during the 2nd quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company's stock worth $268,000 after buying an additional 64 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on JNJ. Citigroup lifted their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a "buy" rating in a research report on Wednesday, October 16th. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, September 14th. Guggenheim lifted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Royal Bank of Canada boosted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a report on Wednesday, October 16th. Finally, Morgan Stanley boosted their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus price target of $175.94.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Down 1.2 %

JNJ stock traded down $1.80 during midday trading on Tuesday, hitting $152.97. The stock had a trading volume of 8,231,159 shares, compared to its average volume of 7,024,149. The firm has a market cap of $368.29 billion, a PE ratio of 22.14, a price-to-earnings-growth ratio of 2.74 and a beta of 0.53. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company's 50-day moving average price is $160.83 and its 200 day moving average price is $156.19.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the previous year, the business posted $2.66 EPS. The business's quarterly revenue was up 5.2% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.24%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson's payout ratio is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.